{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:03:51Z","timestamp":1793754231212,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["Clinical Scientist Award"],"award-info":[{"award-number":["Clinical Scientist Award"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["Gene Therapy Resource Program RSA 1141"],"award-info":[{"award-number":["Gene Therapy Resource Program RSA 1141"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["Research Foundation Grant"],"award-info":[{"award-number":["Research Foundation Grant"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aruvant Sciences, Inc. (Research Grant) Charles H Dater Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41591-025-03662-2","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:02:17Z","timestamp":1748235737000},"page":"2204-2212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Michael","family":"Grimley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Shova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Asnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Sayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-2175","authenticated-orcid":false,"given":"Charles T.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Niss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Lutzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinda A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-1663","authenticated-orcid":false,"given":"Mengna","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosia A.","family":"Kalfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0939-1648","authenticated-orcid":false,"given":"Jennifer","family":"Knight-Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paritha I.","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie N.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-7928","authenticated-orcid":false,"given":"Scott","family":"Witting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-4056","authenticated-orcid":false,"given":"Frederic D.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2108","authenticated-orcid":false,"given":"Punam","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"3662_CR1","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt, O. S. et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639\u20131644 (1994).","journal-title":"N. Engl. J. Med."},{"key":"3662_CR2","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1001\/jama.2022.16732","volume":"328","author":"N Vlachadis","year":"2022","unstructured":"Vlachadis, N. & Vrachnis, N. A review of sickle cell disease. JAMA 328, 1979 (2022).","journal-title":"JAMA"},{"key":"3662_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","volume":"328","author":"PL Kavanagh","year":"2022","unstructured":"Kavanagh, P. L., Fasipe, T. A. & Wun, T. Sickle cell disease: a review. JAMA 328, 57\u201368 (2022).","journal-title":"JAMA"},{"key":"3662_CR4","first-page":"100","volume":"2","author":"MC Walters","year":"1996","unstructured":"Walters, M. C. et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 2, 100\u2013104 (1996).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3662_CR5","doi-asserted-by":"publisher","unstructured":"Townes T. M. Gene replacement therapy for sickle cell disease and other blood disorders. Hematology Am. Soc. Hematol. Educ. Program. https:\/\/doi.org\/10.1182\/asheducation-2008.1.193 (2008).","DOI":"10.1182\/asheducation-2008.1.193"},{"key":"3662_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2029392","volume":"384","author":"EB Esrick","year":"2021","unstructured":"Esrick, E. B. et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N. Engl. J. Med. 384, 205\u2013215 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3662_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3662_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.201000083","volume":"8","author":"EA Roselli","year":"2010","unstructured":"Roselli, E. A. et al. Correction of \u03b2-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol. Med. 8, 315\u2013328 (2010).","journal-title":"EMBO Mol. Med."},{"key":"3662_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter, J. et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N. Engl. J. Med. 386, 617\u2013628 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3662_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ajh.26741","volume":"98","author":"J Kanter","year":"2023","unstructured":"Kanter, J. et al. Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am. J. Hematol. 98, 11\u201322 (2023).","journal-title":"Am. J. Hematol."},{"key":"3662_CR11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2009-01-201863","volume":"114","author":"A Perumbeti","year":"2009","unstructured":"Perumbeti, A. et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114, 1174\u20131185 (2009).","journal-title":"Blood"},{"key":"3662_CR12","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","volume":"4","author":"MM Hsieh","year":"2020","unstructured":"Hsieh, M. M. et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 4, 2058\u20132063 (2020).","journal-title":"Blood Adv."},{"key":"3662_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","volume":"19","author":"UD Bayraktar","year":"2013","unstructured":"Bayraktar, U. D., Bashir, Q., Qazilbash, M., Champlin, R. E. & Ciurea, S. O. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 19, 344\u2013356 (2013).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3662_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/jha2.977","volume":"5","author":"D Melotti","year":"2024","unstructured":"Melotti, D. et al. Outcomes of melphalan 140 mg\/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: single-centre experience. EJHaem 5, 1102\u20131106 (2024).","journal-title":"EJHaem"},{"key":"3662_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.12082","volume":"90","author":"S Matthes-Martin","year":"2013","unstructured":"Matthes-Martin, S. et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur. J. Haematol. 90, 308\u2013312 (2013).","journal-title":"Eur. J. Haematol."},{"key":"3662_CR16","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.bbmt.2017.05.027","volume":"23","author":"A Abraham","year":"2017","unstructured":"Abraham, A. et al. Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol. Blood Marrow Transplant. 23, 1587\u20131592 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3662_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","volume":"18","author":"NR Kamani","year":"2012","unstructured":"Kamani, N. R. et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol. Blood Marrow Transplant. 18, 1265\u20131272 (2012).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3662_CR18","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","volume":"128","author":"S Shenoy","year":"2016","unstructured":"Shenoy, S. et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood 128, 2561\u20132567 (2016).","journal-title":"Blood"},{"key":"3662_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","volume":"69","author":"CE Nath","year":"2010","unstructured":"Nath, C. E. et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br. J. Clin. Pharmacol. 69, 484\u2013497 (2010).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3662_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/bloodadvances.2022008137","volume":"7","author":"A Leonard","year":"2023","unstructured":"Leonard, A. et al. Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease. Blood Adv. 7, 227\u2013234 (2023).","journal-title":"Blood Adv."},{"key":"3662_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.15169","volume":"184","author":"DS Darbari","year":"2019","unstructured":"Darbari, D. S. et al. Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant. Br. J. Haematol. 184, 690\u2013693 (2019).","journal-title":"Br. J. Haematol."},{"key":"3662_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/bloodadvances.2023011013","volume":"8","author":"MAE Rab","year":"2024","unstructured":"Rab, M. A. E. et al. Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease. Blood Adv. 8, 276\u2013286 (2024).","journal-title":"Blood Adv."},{"key":"3662_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1172\/JCI103129","volume":"34","author":"MR Becklake","year":"1955","unstructured":"Becklake, M. R., Griffiths, S. B., Mc, G. M., Goldman, H. I. & Schreve, J. P. Oxygen dissociation curves in sickle cell anemia and in subjects with the sickle cell trait. J. Clin. Invest. 34, 751\u2013755 (1955).","journal-title":"J. Clin. Invest."},{"key":"3662_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1164\/ajrccm.159.2.9806108","volume":"159","author":"FO Ortiz","year":"1999","unstructured":"Ortiz, F. O., Aldrich, T. K., Nagel, R. L. & Benjamin, L. J. Accuracy of pulse oximetry in sickle cell disease. Am. J. Respir. Crit. Care Med. 159, 447\u2013451 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3662_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12955-014-0125-0","volume":"12","author":"SD Keller","year":"2014","unstructured":"Keller, S. D., Yang, M., Treadwell, M. J., Werner, E. M. & Hassell, K. L. Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks. Health Qual. Life Outcomes 12, 125 (2014).","journal-title":"Health Qual. Life Outcomes"},{"key":"3662_CR26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/science.278.5339.873","volume":"278","author":"TM Ryan","year":"1997","unstructured":"Ryan, T. M., Ciavatta, D. J. & Townes, T. M. Knockout-transgenic mouse model of sickle cell disease. Science 278, 873\u2013876 (1997).","journal-title":"Science"},{"key":"3662_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.ymthe.2020.12.036","volume":"29","author":"L Breda","year":"2021","unstructured":"Breda, L. et al. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies. Mol. Ther. 29, 1625\u20131638 (2021).","journal-title":"Mol. Ther."},{"key":"3662_CR28","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","volume":"102","author":"DN Levasseur","year":"2003","unstructured":"Levasseur, D. N., Ryan, T. M., Pawlik, K. M. & Townes, T. M. Correction of a mouse model of sickle cell disease: lentiviral\/antisickling \u03b2-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102, 4312\u20134319 (2003).","journal-title":"Blood"},{"key":"3662_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12456-3","volume":"10","author":"N Uchida","year":"2019","unstructured":"Uchida, N. et al. Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders. Nat. Commun. 10, 4479 (2019).","journal-title":"Nat. Commun."},{"key":"3662_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. Therapeutic base editing of human hematopoietic stem cells. Nat. Med. 26, 535\u2013541 (2020).","journal-title":"Nat. Med."},{"key":"3662_CR31","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41588-023-01434-7","volume":"55","author":"T Mayuranathan","year":"2023","unstructured":"Mayuranathan, T. et al. Potent and uniform fetal hemoglobin induction via base editing. Nat. Genet. 55, 1210\u20131220 (2023).","journal-title":"Nat. Genet."},{"key":"3662_CR32","first-page":"2085","volume":"141","author":"C Li","year":"2023","unstructured":"Li, C. et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood 141, 2085\u20132099 (2023).","journal-title":"Blood"},{"key":"3662_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","volume":"595","author":"GA Newby","year":"2021","unstructured":"Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295\u2013302 (2021).","journal-title":"Nature"},{"key":"3662_CR34","doi-asserted-by":"publisher","first-page":"eabf2444","DOI":"10.1126\/scitranslmed.abf2444","volume":"13","author":"A Lattanzi","year":"2021","unstructured":"Lattanzi, A. et al. Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci. Transl. Med. 13, eabf2444 (2021).","journal-title":"Sci. Transl. Med."},{"key":"3662_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa2215643","volume":"389","author":"A Sharma","year":"2023","unstructured":"Sharma, A. et al. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. N. Engl. J. Med. 389, 820\u2013832 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3662_CR36","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).","journal-title":"Sci. Transl. Med."},{"key":"3662_CR37","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1172\/JCI67930","volume":"123","author":"Z Romero","year":"2013","unstructured":"Romero, Z. et al. \u03b2-globin gene transfer to human bone marrow for sickle cell disease. J. Clin. Invest. 123, 3317\u20133330 (2013).","journal-title":"J. Clin. Invest."},{"key":"3662_CR38","unstructured":"CASGEVY (STN125785). FDA www.fda.gov\/vaccines-blood-biologics\/casgevy (2024)."},{"key":"3662_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1073\/pnas.76.2.670","volume":"76","author":"RL Nagel","year":"1979","unstructured":"Nagel, R. L. et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc. Natl Acad. Sci. USA 76, 670\u2013672 (1979).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3662_CR40","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","volume":"29","author":"M Spencer Chapman","year":"2023","unstructured":"Spencer Chapman, M. et al. Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease. Nat. Med. 29, 3175\u20133183 (2023).","journal-title":"Nat. Med."},{"key":"3662_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.exphem.2004.02.003","volume":"32","author":"L Luck","year":"2004","unstructured":"Luck, L., Zeng, L., Hiti, A. L., Weinberg, K. I. & Malik, P. Human CD34+ and CD34+CD38\u2212 hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Exp. Hematol. 32, 483\u2013493 (2004).","journal-title":"Exp. Hematol."},{"key":"3662_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtm.2016.11.003","volume":"4","author":"CC Berry","year":"2017","unstructured":"Berry, C. C. et al. INSPIIRED: quantification and visualization tools for analyzing integration site distributions. Mol. Ther. Methods Clin. Dev. 4, 17\u201326 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3662_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.omtm.2016.11.002","volume":"4","author":"E Sherman","year":"2017","unstructured":"Sherman, E. et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol. Ther. Methods Clin. Dev. 4, 39\u201349 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3662_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/bioinformatics\/bts004","volume":"28","author":"CC Berry","year":"2012","unstructured":"Berry, C. C. et al. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 28, 755\u2013762 (2012).","journal-title":"Bioinformatics"},{"key":"3662_CR45","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1038\/sj.mt.6300259","volume":"15","author":"PI Arumugam","year":"2007","unstructured":"Arumugam, P. I. et al. Improved human \u03b2-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol. Ther. 15, 1863\u20131871 (2007).","journal-title":"Mol. Ther."},{"key":"3662_CR46","doi-asserted-by":"publisher","first-page":"e6995","DOI":"10.1371\/journal.pone.0006995","volume":"4","author":"PI Arumugam","year":"2009","unstructured":"Arumugam, P. I. et al. The 3\u2032 region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS ONE 4, e6995 (2009).","journal-title":"PLoS ONE"},{"key":"3662_CR47","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/mt.2009.89","volume":"17","author":"F Urbinati","year":"2009","unstructured":"Urbinati, F. et al. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3\u2032LTR. Mol. Ther. 17, 1527\u20131536 (2009).","journal-title":"Mol. Ther."},{"key":"3662_CR48","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/mt.2009.183","volume":"17","author":"PI Arumugam","year":"2009","unstructured":"Arumugam, P. I. et al. Genotoxic potential of lineage-specific lentivirus vectors carrying the \u03b2-globin locus control region. Mol. Ther. 17, 1929\u20131937 (2009).","journal-title":"Mol. Ther."},{"key":"3662_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/blood-2009-09-244830","volume":"116","author":"N Sundaram","year":"2010","unstructured":"Sundaram, N. et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood 116, 109\u2013112 (2010).","journal-title":"Blood"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03662-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03662-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03662-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:48:36Z","timestamp":1757173716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03662-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3662"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03662-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M. has received royalties, research funding and consulting fees from Aruvant Sciences. P.K. is the Co-Chair of the CIBMTR GVHD working committee; C.T.Q. is a Member of the SCD Task Force, American Society of Hematology (ASH); J.K.-M. is a member of the Hydroxyurea Guidelines Development Group for SCD, ASH; T.A.K. is a member of the Scientific Committee on Blood Disorders in Childhood, ASH; S.M.D. is on the Advisory Board of Polarean; P.M. has memberships on the Global Gene Therapy Initiative, Publications Committee, American Society of Cell and Gene Therapy (ASGCT), and the Hematopoiesis and PID Committee, European Society of Gene and Cell Therapy. She is also on the ASGCT Board of Directors. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}